Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

Study Overview
=================
Brief Summary
-----------------
This is a single arm, open-label, phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T, an autologous tri-functional anti- CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in Refractory/ Relapsed CD19 Positive Non-Hodgkin Lymphoma (NHL).

Detailed Description
-----------------
The tri-functional anti-CD19 chimeric antigen receptor contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the CD19-TriCAR-T to simultaneously targeting the CD19 positive NHL cells，blocking the inhibitory PD-L1 signal and stimulating T/NK cell activation and expansion.

Official Title
-----------------
Adoptive Immunotherapy for Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cells

Conditions
-----------------
Non-hodgkin Lymphoma,B Cell

Intervention / Treatment
-----------------
* Biological: CD19-TriCAR-T


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All subjects must personally sign and date the consent form before initiating any study specific procedures or activities; All subjects must be able to comply with all the scheduled procedures in the study; Histologically or cytologically confirmed CD19 positive non-Hodgkin lymphoma; At least one measurable lesion per revised IWG Response Criteria; Aged 18 to 69 years; Expected survival ≥12 weeks; Eastern cooperative oncology group (ECOG) performance status of ≤2; Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks; All other treatment induced adverse events must have been resolved to ≤grade 1; Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB >70g/L, Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN, Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome); Exclusion Criteria: Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment; Patients with symptomatic central nervous system metastasis, intracranial metastasis, and cancer cells found in cerebrospinal fluid are not recommended to participate in this study. Symptom free or post-treatment stable disease or disappearance of lesions should not be excluded. The specific selection is ultimately determined by the investigator; Lactating women; Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCV positive); Known history of infection with HIV; Subjects need systematic usage of corticosteroid; Subjects need systematic usage of immunosuppressive drug; Planed operation, history of other related disease, or any other related laboratory tests restrict patients for the study; Other reasons the investigator think the patient may not be suitable for the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CD19-TriCAR-T<br>Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously | Biological: CD19-TriCAR-T<br>* A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10^6 CAR+ T cells/kg body weight.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03） | Incidence of treatment-related adverse events as assessed by CTCAE v4.03 | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma) | Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma | 24 months | 
| Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria） | Partial response rate per the revised International Working Group (IWG) Response Criteria | 24 months | 
| Duration of Response （The time from response to relapse or progression） | The time from response to relapse or progression | 24 months | 
| Progression Free Survival （The time from the first day of treatment to the date on which disease progresses） | The time from the first day of treatment to the date on which disease progresses | 24 months | 
| Overall Survival （The number of patient alive, with or without signs of cancer） | The number of patient alive, with or without signs of cancer | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CAR-T, TriCAR-T, CD19-TriCAR-T, Non-hodgkin Lymphoma, NHL, CD19-CAR-T